Bifogade filer
Kurs
-0,78%
Likviditet
0,12 MSEK
Kalender
Est. tid* | ||
2025-11-21 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-08-29 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-05-28 | 08:30 | Kvartalsrapport 2025-Q1 |
2025-05-19 | N/A | X-dag ordinarie utdelning ISAB 0.00 SEK |
2025-05-16 | N/A | Årsstämma |
2025-05-08 | - | Extra Bolagsstämma 2025 |
2025-02-28 | - | Bokslutskommuniké 2024 |
2024-11-20 | - | Kvartalsrapport 2024-Q3 |
2024-09-04 | - | Extra Bolagsstämma 2024 |
2024-08-28 | - | Kvartalsrapport 2024-Q2 |
2024-05-28 | - | Kvartalsrapport 2024-Q1 |
2024-05-15 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2024-05-14 | - | Årsstämma |
2024-02-28 | - | Bokslutskommuniké 2023 |
2023-11-22 | - | Kvartalsrapport 2023-Q3 |
2023-08-29 | - | Kvartalsrapport 2023-Q2 |
2023-05-31 | - | Kvartalsrapport 2023-Q1 |
2023-05-15 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2023-05-12 | - | Årsstämma |
2023-02-28 | - | Bokslutskommuniké 2022 |
2022-11-22 | - | Kvartalsrapport 2022-Q3 |
2022-08-29 | - | Kvartalsrapport 2022-Q2 |
2022-06-08 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2022-05-23 | - | Kvartalsrapport 2022-Q1 |
2022-05-06 | - | Årsstämma |
2022-02-28 | - | Bokslutskommuniké 2021 |
2021-11-24 | - | Kvartalsrapport 2021-Q3 |
2021-08-26 | - | Kvartalsrapport 2021-Q2 |
2021-06-22 | - | Extra Bolagsstämma 2021 |
2021-06-09 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2021-06-08 | - | Årsstämma |
2021-05-19 | - | Kvartalsrapport 2021-Q1 |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-11-26 | - | Kvartalsrapport 2020-Q3 |
2020-08-26 | - | Kvartalsrapport 2020-Q2 |
2020-06-12 | - | Extra Bolagsstämma 2020 |
2020-05-13 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2020-05-12 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-20 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-22 | - | Årsstämma |
2019-05-16 | - | Kvartalsrapport 2019-Q1 |
2019-05-10 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2019-02-21 | - | Bokslutskommuniké 2018 |
2018-12-13 | - | Extra Bolagsstämma 2018 |
2018-11-15 | - | Kvartalsrapport 2018-Q3 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-24 | - | X-dag ordinarie utdelning ISAB 0.00 SEK |
2018-05-23 | - | Årsstämma |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-22 | - | Bokslutskommuniké 2017 |
2017-11-17 | - | Kvartalsrapport 2017-Q3 |
2017-08-28 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
(Stockholm, Sverige, 12 April 2022) Inhalation Sciences AB has signed a new distribution with Quantaflux Industrial Co. Ltd that will cover the crucial China, Hong Kong and Macau markets. CEO Manoush Masarrat: "China is an important market for inhaled medicine, with robust R&D and a high level of local investment. We are delighted to be partnering With Quantaflux Industrial."
Quantaflux Industrial Co. Ltd is a Labtech distributor for lab testing instruments covering China, Hong Kong and Macau. The company has strong ties to China's extensive network of inhalation drug R&D labs as a distributor of instruments for inhaler testing.
ISAB represents a positive complement for Quantaflux's portfolio, enabling the company to expand its current offering beyond inhaler delivery devices and into substance and drug development studies - through ISAB's range of novel instruments for precision performance in preclinical PK (Pharmacokinetics) studies.
Ruty Li, General Manager of Quantaflux Industrial: "We are very glad to be the distributor of ISAB, an innovator in preclinical in vitro and in vivo PK tests. We hope we can contribute to the development of the Chinese OINDP (Orally Inhaled and Nasal Drug Products) market with the flagship products of ISAB and our support."
ISAB CEO Manoush Masarrat: "China is a key market for inhalation drug development and inhaled generics companies with a robust R&D sector and a high level of local investment. We look forward to partnering with Quantaflux Industries and expanding our customer base in these crucial markets."
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se